Methods of treating a neoplasia with IL-15-based molecules and CTLA-4 antibody
The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
1. A method for treating a CTLA-4 ligand expressing neoplasia in a subject, the method comprising: administering to said subject a pharmaceutical composition comprising an effective amount of an isolated anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody and an effective amount of an IL-15:IL-15RαSu complex, wherein the effective amount of the IL-15:IL-15RαSu complex is between 0.1 μg/kg and 100 mg/kg, thereby treating the neoplasia.
2. The method of claim 1 , wherein the IL-15:IL-15RαSu complex comprises a wild type IL-15 molecule.
3. The method of claim 1 , wherein the IL-15:IL-15RαSu complex comprises an IL-15 molecule having the amino acid sequence of SEQ ID NO:3.
4. The method of claim 1 , wherein the IL-15:IL-15RαSu complex comprises an IL-15RαSuFc fusion construct, having the amino acid sequence of SEQ ID NO:6.
5. The method of claim 1 , wherein the IL-15:IL-15RαSu complex is Alt-803.
6. The method of claim 1 , wherein the subject is suffering from a CTLA-4 ligand expressing neoplasia and the neoplasia is selected from the group consisting of a glioblastoma, prostate cancer, multiple myeloma, B-cell lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, cutaneous T-cell lymphoma, T-cell lymphoma, urothelial carcinoma, bladder carcinoma, melanoma, lung cancer, renal cell carcinoma, breast cancer, gastric cancer, esophageal cancer, head and neck cancer, colorectal cancer, ovarian cancer, non-small cell lung carcinoma (NSCLC), B-Cell non-Hodgkin's lymphoma, and squamous cell head and neck carcinoma.
7. The method of claim 6 , wherein the subject is suffering from melanoma, renal cell carcinoma, or NSCLC.
8. The method of claim 1 , wherein the effective amount of the IL-15:IL-15RαSu complex is administered daily.
9. The method of claim 1 , wherein the effective amount of the IL-15:IL-15RαSu complex is administered once or twice per week.
10. The method of claim 1 , wherein the effective amount of the IL-15:IL-15RαSu complex is between 0.1 μg/kg and 1 mg/kg.
11. The method of claim 1 , wherein the pharmaceutical composition is administered by subcutaneous, intravenous, intraperitoneal, intramuscular, or intradermal injection, or by intravesicular instillation.
12. The method of claim 1 , wherein the anti-CTLA-4 antibody is ipilimumab, ticilimumab, tremelimumab.
13. The method of claim 1 , wherein antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) mediated by said antibody against tumor cells in said subject is induced following said administration.
14. The method of claim 1 , wherein said antibody and the IL-15:IL-15RαSu complex increases levels of blood NK cell, T cell, neutrophil or monocyte counts or activity.
15. The method of claim 1 , wherein said antibody and the IL-15:IL-15RαSu complex stimulate CD4+ or CD8+ T cells to kill tumor cells.
16. The method of claim 1 , wherein said antibody and the IL-15:IL-15RαSu complex stimulate NK cells to kill tumor cells.
17. The method of claim 1 , wherein said antibody and the IL-15:IL-15RαSu complex stimulate neutrophils or monocytic cells to kill tumor cells.
18. The method of claim 1 , wherein said administration results in a decrease in the number of tumor cells.
19. The method of claim 1 , wherein said administration results in a decrease in disease progression of the neoplasia.
20. The method of claim 1 , wherein said administration results in prolonged survival of said subject compared to untreated subjects.
21. The method of claim 1 , wherein said subject is a human.
22. The method of claim 1 , wherein said antibody and the IL-15:IL-15RαSu complex increase blood cytokine levels.
23. The method of claim 22 , wherein said cytokine is interferon-gamma (IFN-γ) or interleukin-6 (IL-6).